MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-27-2026
AIM ImmunoTech ROCE Ratio 2011-2026 | AIM
Annual ROCE Ratio AIM ImmunoTech
| 2025 | 2024 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 119.23 | 1495.61 | -51.79 | -33.12 | 1868.25 | -65.17 | -134.41 | -99.27 | -83.98 | -81.73 | -76.38 | -58.52 | -45.15 | -37.18 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1868.25 | -134.41 | 194.03 |
Quarterly ROCE Ratio AIM ImmunoTech
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 20.36 | -174.06 | -275.02 | -333.51 | -369.6 | -251.53 | -209.12 | -66.49 | -81.76 | -60.94 | -52.45 | -30.81 | -37.14 | -28.2 | -24.25 | -17.28 | -22.76 | -21.9 | -21.67 | -16.35 | -41.18 | -60.54 | -80.07 | -72.48 | -131.2 | -165.08 | -202.47 | -170.76 | -201.23 | -172.99 | -141.98 | -99.08 | -119.9 | -110.24 | -97.03 | -62.71 | -82.26 | -81.0 | -86.9 | -67.78 | -84.2 | -81.06 | -77.34 | -57.2 | -72.42 | -71.22 | -67.04 | -46.95 | -58.06 | -53.94 | -45.91 | -27.62 | -36.99 | -35.25 | -35.68 | -27.38 | -9.37 | -8.56 | -9.46 |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 20.36 | -369.6 | -88.59 |
ROCE Ratio of other stocks in the Biotechnology industry
| Issuer | ROCE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
2.89 | - | 2.43 % | $ 254 M |  Germany |
 |
Aligos Therapeutics
ALGS
|
-164.32 | $ 8.74 | 0.23 % | $ 86.4 M |  USA |
 |
Allakos
ALLK
|
-116.14 | - | - | $ 28.6 M | USA |
 |
Alterity Therapeutics Limited
ATHE
|
-104.38 | $ 3.62 | -1.09 % | $ 8.71 B |  Australia |
 |
Aptinyx
APTX
|
-163.42 | - | -39.0 % | $ 4.57 M | USA |
 |
Aravive
ARAV
|
-664.7 | - | -13.39 % | $ 1.45 M | USA |
 |
BioNTech SE
BNTX
|
-4.81 | $ 98.41 | 1.77 % | $ 27.2 B | Germany |
 |
Burford Capital Limited
BUR
|
14.24 | $ 4.71 | 4.9 % | $ 760 M |  Britain |
 |
Cabaletta Bio
CABA
|
-153.72 | $ 3.26 | 1.87 % | $ 328 M | USA |
 |
AlloVir
ALVR
|
-58.56 | - | 4.14 % | $ 49.1 M | USA |
 |
Applied Molecular Transport
AMTI
|
-209.11 | - | - | $ 10.1 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
17.36 | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
-49.48 | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
-325.06 | - | -13.47 % | $ 169 M | France |
 |
Brainstorm Cell Therapeutics
BCLI
|
163.63 | - | -2.5 % | $ 5.88 M | USA |
 |
Applied Therapeutics
APLT
|
394.73 | - | - | $ 8.42 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-61.36 | - | -1.52 % | $ 24.7 M | USA |
 |
BeiGene, Ltd.
BGNE
|
7.03 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
bluebird bio
BLUE
|
-125.56 | - | - | $ 546 M | USA |
 |
Midatech Pharma plc
MTP
|
-337.43 | - | -18.52 % | $ 27.3 M | Britain |
 |
Amphastar Pharmaceuticals
AMPH
|
17.8 | $ 21.38 | 0.09 % | $ 999 M | USA |
 |
Checkpoint Therapeutics
CKPT
|
444.94 | - | - | $ 169 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
15.18 | - | - | - |  Russia |
 |
Adverum Biotechnologies
ADVM
|
-196.79 | - | - | $ 86.2 M | USA |
 |
Advaxis
ADXS
|
429.74 | - | -9.65 % | $ 45.9 M | USA |
 |
Clearside Biomedical
CLSD
|
156.13 | - | - | $ 25.3 M | USA |
 |
Aeterna Zentaris
AEZS
|
-29.95 | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
64924.32 | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-29.3 | - | - | $ 1.01 B | USA |
 |
Akebia Therapeutics
AKBA
|
72.06 | $ 1.56 | 6.12 % | $ 401 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-60.13 | - | - | $ 26.5 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-146.69 | $ 3.05 | 4.45 % | $ 5.02 M |  Israel |
 |
Aquestive Therapeutics
AQST
|
211.07 | $ 4.15 | -0.95 % | $ 444 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
-6.45 | $ 25.09 | 4.02 % | $ 3.19 B | USA |
 |
Chimerix
CMRX
|
-48.21 | - | - | $ 756 M | USA |
 |
Concert Pharmaceuticals
CNCE
|
-69.06 | - | - | $ 401 M | USA |
 |
AIkido Pharma
AIKI
|
-80.33 | - | 1.93 % | $ 17.4 M | USA |
 |
Celldex Therapeutics
CLDX
|
-54.51 | $ 33.33 | 2.27 % | $ 2.21 B | USA |
 |
Autolus Therapeutics plc
AUTL
|
-151.88 | $ 1.48 | 0.68 % | $ 394 M | Britain |
 |
Aptose Biosciences
APTO
|
-46.69 | - | -45.71 % | $ 1.2 M | Canada |
 |
Cidara Therapeutics
CDTX
|
-107.83 | - | - | $ 1.41 B | USA |
 |
Evogene Ltd.
EVGN
|
-39.87 | $ 0.82 | 0.02 % | $ 27.9 M | Israel |
 |
AVROBIO
AVRO
|
10.76 | - | 1083.1 % | $ 745 M | USA |
|
Forte Biosciences
FBRX
|
-115.85 | $ 32.42 | 5.95 % | $ 420 M | USA |
 |
CNS Pharmaceuticals
CNSP
|
-353.49 | $ 2.64 | 8.42 % | $ 1.17 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
3412.47 | - | - | $ 7.46 M | Israel |
 |
AstraZeneca PLC
AZN
|
11.12 | - | - | $ 96.9 B | Britain |
 |
Akero Therapeutics
AKRO
|
-38.05 | - | - | $ 3.67 B | USA |
 |
CTI BioPharma Corp.
CTIC
|
453.99 | - | - | $ 1.2 B | USA |